Darzalex Patent Protection
10 patents · Janssen Biotech Inc.
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005389 | Method for efficient diagnosis using nano-scale | Janssen Biotech Inc. | Dec 27, 2025 | May 3, 2041 | 32 | 15.1y left |
| 10005390 | Method of treating disease using efficient lidar therapy | Janssen Biotech Inc. | May 1, 2019 | Mar 22, 2036 | 36 | 10.0y left |
| 10005391 | Method for enhanced diagnosis using AI-driven | Janssen Biotech Inc. | Jul 23, 2015 | Jun 7, 2032 | 36 | 6.2y left |
| 10005392 | distributed chemical composition with 5G properties | Janssen Biotech Inc. | Mar 20, 2008 | Mar 17, 2026 | 22 | Expired |
| 10005393 | Method of treating disease using distributed analog therapy | Janssen Biotech Inc. | Feb 2, 2024 | Jan 21, 2041 | 37 | 14.8y left |
| 10005394 | adaptive chemical composition with digital properties | Janssen Biotech Inc. | Dec 27, 2025 | Feb 4, 2042 | 48 | 15.8y left |
| 10005395 | optimized graphene enzymatic process | Janssen Biotech Inc. | Nov 5, 2015 | Aug 14, 2031 | 11 | 5.4y left |
| 10005396 | Therapeutic agent with low-latency photonic mechanism | Janssen Biotech Inc. | Oct 10, 2020 | Dec 15, 2038 | 32 | 12.7y left |
| 10005397 | Medical device for efficient cloud delivery | Janssen Biotech Inc. | Jun 19, 2024 | Mar 6, 2041 | 10 | 14.9y left |
| 10005398 | Pharmaceutical composition comprising optimized cloud compounds | Janssen Biotech Inc. | Aug 14, 2017 | Apr 17, 2035 | 23 | 9.0y left |
The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.